Resource Summary Report

Generated by RRID on Jul 30, 2026

Brilliant Violet 785(TM) anti-mouse CD103

RRID:AB_2800588
Type: Antibody

Proper Citation

BioLegend Cat# 121439, RRID:AB_2800588

Antibody Information

URL: http://antibodyregistry.org/AB_2800588

Proper Citation: BioLegend Cat# 121439, RRID:AB_2800588

Target Antigen: CD103

Host Organism: armenian hamster

Clonality: monoclonal

Comments: Applications: FC

Antibody Name: Brilliant Violet 785(TM) anti-mouse CD103

Description: This monoclonal targets CD103

Target Organism: mouse

Clone ID: Clone 2E7

Antibody ID: AB_2800588

Vendor: BioLegend

Catalog Number: 121439

Record Creation Time: 20250820T061515+0000

Record Last Update: 20250820T233805+0000

Ratings and Alerts

No rating or validation information has been found for Brilliant Violet 785(TM) anti-mouse CD103.

No alerts have been found for Brilliant Violet 785(TM) anti-mouse CD103.

Data and Source Information

Source: Antibody Registry

Usage and Citation Metrics

We found 11 mentions in open access literature.

Listed below are recent publications. The full list is available at RRID .

Xiao Z, et al. (2025) Engineered T cells stimulate dendritic cell recruitment and antigen spreading for potent anti-tumor immunity. Cell reports. Medicine, 6(9), 102307.

Vidal SJ, et al. (2025) Mining the CD4 antigen repertoire for next-generation tuberculosis vaccines. Cell.

Lecointre M, et al. (2025) HPV16-Expressing Tumors Release Multiple IL1 Ligands to Orchestrate Systemic Immunosuppression Whose Disruption Enables Efficacy of a Therapeutic Vaccine. Cancer discovery, 15(7), 1458.

Wang L, et al. (2025) Mucosal boosting increases protective efficacy of an influenza vaccine in mice. iScience, 28(6), 112721.

Wang M, et al. (2025) Vascular Normalization Augments the Antitumor Efficacy of Combined HDAC Inhibitor with Immunotherapy in Solid Tumors. Cancer discovery, 15(9), 1883.

Castaño D, et al. (2025) Distinct components of mRNA vaccines cooperate to instruct efficient germinal center responses. Cell, 188(26), 7461.

Ziblat A, et al. (2024) Batf3+ DCs and the 4-1BB/4-1BBL axis are required at the effector phase in the tumor microenvironment for PD-1/PD-L1 blockade efficacy. Cell reports, 43(5), 114141.

Dean JW, et al. (2023) The aryl hydrocarbon receptor cell intrinsically promotes resident memory CD8+ T cell differentiation and function. Cell reports, 42(1), 111963.

Gurram RK, et al. (2023) Crosstalk between ILC2s and Th2 cells varies among mouse models. Cell reports, 42(2), 112073.

Lin YH, et al. (2023) Small intestine and colon tissue-resident memory CD8+ T cells exhibit molecular heterogeneity and differential dependence on Eomes. Immunity, 56(1), 207.

Zhou R, et al. (2022) Nasal prevention of SARS-CoV-2 infection by intranasal influenza-based boost vaccination in mouse models. EBioMedicine, 75, 103762.